• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients.嵌合抗原受体T细胞疗法治疗多发性骨髓瘤：对950例患者的系统评价和荟萃分析
Blood Adv. 2021 Feb 23;5(4):1097-1101. doi: 10.1182/bloodadvances.2020004017.
2
Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients.高危疾病对嵌合抗原受体T细胞疗法治疗多发性骨髓瘤疗效的影响：一项对723例患者的荟萃分析
Haematologica. 2023 Oct 1;108(10):2799-2802. doi: 10.3324/haematol.2022.282510.
3
Chimeric Antigen Receptor T-Cell Therapy for Patients With Multiple Myeloma-A Call for Equal Opportunity.嵌合抗原受体T细胞疗法用于多发性骨髓瘤患者——呼吁平等机会
JAMA Oncol. 2023 Mar 1;9(3):297-298. doi: 10.1001/jamaoncol.2022.6834.
4
Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment.嵌合抗原受体T细胞疗法在肾功能不全的复发/难治性多发性骨髓瘤中的安全性和有效性
Bone Marrow Transplant. 2020 Nov;55(11):2215-2218. doi: 10.1038/s41409-020-0930-5. Epub 2020 May 9.
5
Chimeric Antigen Receptor T Cells in Multiple Myeloma.嵌合抗原受体 T 细胞在多发性骨髓瘤中的应用。
Hematol Oncol Clin North Am. 2023 Dec;37(6):1089-1105. doi: 10.1016/j.hoc.2023.05.008. Epub 2023 Aug 8.
6
[Development of next-generation chimeric antigen receptor-engineered T-cell therapy].[下一代嵌合抗原受体工程化T细胞疗法的发展]
Rinsho Ketsueki. 2022;63(9):1290-1297. doi: 10.11406/rinketsu.63.1290.
7
Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤前的桥接治疗。
Br J Haematol. 2024 Feb;204(2):449-454. doi: 10.1111/bjh.19227. Epub 2023 Nov 30.
8
Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead.嵌合抗原受体 T 细胞治疗多发性骨髓瘤：迄今为止的历程和未来的道路。
Cancer J. 2021;27(2):112-118. doi: 10.1097/PPO.0000000000000506.
9
Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体T细胞疗法后髓系肿瘤相关的特征和因素
JAMA Oncol. 2024 Apr 1;10(4):532-535. doi: 10.1001/jamaoncol.2023.7182.
10
[Chimeric antigen receptor T-cell therapy for multiple myeloma].嵌合抗原受体T细胞疗法治疗多发性骨髓瘤
Rinsho Ketsueki. 2018;59(10):2189-2194. doi: 10.11406/rinketsu.59.2189.

引用本文的文献

1
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.多发性骨髓瘤的免疫治疗：当下现状预示未来发展。
Int J Mol Sci. 2023 Oct 27;24(21):15674. doi: 10.3390/ijms242115674.
2
Fitness and frailty in myeloma.骨髓瘤患者的健康与虚弱。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):337-348. doi: 10.1182/hematology.2022000346.
3
Progress on CAR-T cell therapy for hematological malignancies.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤的研究进展。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Apr 25;51(2):192-203. doi: 10.3724/zdxbyxb-2022-0055.
4
Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.了解多发性骨髓瘤中常用表面抗原的生物活性及预后意义
J Clin Med. 2022 Mar 25;11(7):1809. doi: 10.3390/jcm11071809.
5
Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma.用于评估多发性骨髓瘤患者治疗反应和预后的血清异常代谢物
Front Oncol. 2022 Feb 28;12:808290. doi: 10.3389/fonc.2022.808290. eCollection 2022.
6
Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.嵌合抗原受体 (CAR) T 细胞治疗血液系统恶性肿瘤的不良反应：系统评价和 Meta 分析。
BMC Cancer. 2022 Jan 24;22(1):98. doi: 10.1186/s12885-021-09102-x.
7
AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.AHSA1 是多发性骨髓瘤细胞增殖和蛋白酶体抑制剂耐药性的一个有前途的治疗靶点。
J Exp Clin Cancer Res. 2022 Jan 6;41(1):11. doi: 10.1186/s13046-021-02220-1.
8
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.2020年/2021年及以后的复发/难治性多发性骨髓瘤
Cancers (Basel). 2021 Oct 14;13(20):5154. doi: 10.3390/cancers13205154.
9
The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma.单克隆抗体在双特异性抗体和嵌合抗原受体T细胞疗法时代对多发性骨髓瘤的作用
Cancers (Basel). 2021 Sep 29;13(19):4909. doi: 10.3390/cancers13194909.
10
Minimal Residual Disease in Multiple Myeloma: Something Old, Something New.多发性骨髓瘤中的微小残留病：旧貌新颜。
Cancers (Basel). 2021 Aug 27;13(17):4332. doi: 10.3390/cancers13174332.

本文引用的文献

1
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛，一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法，用于治疗复发或难治性多发性骨髓瘤患者（CARTITUDE-1）：一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
2
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.抗CD19嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病：一项系统评价和荟萃分析。
Lancet Haematol. 2020 Nov;7(11):e816-e826. doi: 10.1016/S2352-3026(20)30277-5.
3
Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤。
Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):21-34. doi: 10.1016/j.clml.2020.08.027. Epub 2020 Sep 18.
4
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.多发性骨髓瘤：2020 年诊断、风险分层和治疗更新。
Am J Hematol. 2020 May;95(5):548-567. doi: 10.1002/ajh.25791.
5
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
6
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.B 细胞成熟抗原特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中具有临床活性。
J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397.
7
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
8
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.针对恶性肿瘤相关κ轻链的T淋巴细胞的临床反应。
J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.
9
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.系统评价与Meta分析优先报告条目：PRISMA声明
PLoS Med. 2009 Jul 21;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.
10
Measuring inconsistency in meta-analyses.评估荟萃分析中的异质性
BMJ. 2003 Sep 6;327(7414):557-60. doi: 10.1136/bmj.327.7414.557.

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients.

作者信息

Mohyuddin Ghulam Rehman, Rooney Anthony, Balmaceda Nicole, Aziz Muhammad, Sborov Douglas W, McClune Brian, Kumar Shaji K

机构信息

Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Westwood, KS.

Division of Gastroenterology, University of Toledo, Toledo, OH.

出版信息

Blood Adv. 2021 Feb 23;5(4):1097-1101. doi: 10.1182/bloodadvances.2020004017.

DOI:10.1182/bloodadvances.2020004017
PMID:33606005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7903229/
Abstract
摘要